THE WOODLANDS, TX, USA I December 20, 2018 I Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes.
“Results from our Phase 1 studies build on previously reported promising preclinical data for LX2761 and confirm the drug candidate’s unique preclinical profile as a potent, gastrointestinal tract-selective SGLT1 inhibitor,” said Praveen Tyle, Ph.D., executive vice president of Research and Development. “We are evaluating next steps for this compound and look forward to providing updates in the future.”
The Phase 1 clinical studies of LX2761 included a Phase 1a single ascending-dose study in healthy volunteers and patients with type 2 diabetes, and a Phase 1b multiple ascending-dose study in patients with type 2 diabetes.
The Phase 1a study involved 5 cohorts of healthy volunteers and 2 cohorts of patients with type 2 diabetes. Patients with type 2 diabetes were washed off metformin for 3 days prior to dosing. LX2761 demonstrated minimal absorption and no systemic effect, with no increase in urine glucose excretion from baseline. In addition, LX2761 reduced postprandial glucose in diabetic patients while increasing plasma levels of GLP-1. The most common adverse and dose-limiting event was diarrhea, consistent with the SGLT1mechanism of action due to reduced glucose absorption in the gut.
The randomized, double-blind, placebo-controlled Phase 1b study was performed to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of multiple doses of orally administered LX2761 in patients with type 2 diabetes. Patients were randomly assigned to receive LX2761 or placebo over an 8-day treatment period as either a single dose or twice a day dose at breakfast and dinner. Patients were treated with metformin at the time of screening and for the duration of the study. LX2761 showed reduced postprandial glucose, demonstrating delayed and reduced intestinal glucose absorption while increasing plasma levels of GLP-1 with minimal effect on urinary glucose excretion, consistent with inhibition of intestinal SGLT1. The most common adverse event was diarrhea.
About LX2761
LX2761 is an orally-delivered small molecule compound that is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney. In preclinical studies, LX2761 delayed and reduced intestinal glucose absorption and reduced postprandial glucose while increasing plasma levels of GLP-1 with minimal effect on urinary glucose excretion. Lexicon has granted Sanofi certain rights of first negotiation with respect to the future development and commercialization of LX2761.
About Lexicon Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO® (telotristat ethyl), Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in diabetes and metabolism and neuropathic pain. For additional information please visit www.lexpharma.com.
SOURCE: Lexicon Pharmaceuticals
Post Views: 138
THE WOODLANDS, TX, USA I December 20, 2018 I Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes.
“Results from our Phase 1 studies build on previously reported promising preclinical data for LX2761 and confirm the drug candidate’s unique preclinical profile as a potent, gastrointestinal tract-selective SGLT1 inhibitor,” said Praveen Tyle, Ph.D., executive vice president of Research and Development. “We are evaluating next steps for this compound and look forward to providing updates in the future.”
The Phase 1 clinical studies of LX2761 included a Phase 1a single ascending-dose study in healthy volunteers and patients with type 2 diabetes, and a Phase 1b multiple ascending-dose study in patients with type 2 diabetes.
The Phase 1a study involved 5 cohorts of healthy volunteers and 2 cohorts of patients with type 2 diabetes. Patients with type 2 diabetes were washed off metformin for 3 days prior to dosing. LX2761 demonstrated minimal absorption and no systemic effect, with no increase in urine glucose excretion from baseline. In addition, LX2761 reduced postprandial glucose in diabetic patients while increasing plasma levels of GLP-1. The most common adverse and dose-limiting event was diarrhea, consistent with the SGLT1mechanism of action due to reduced glucose absorption in the gut.
The randomized, double-blind, placebo-controlled Phase 1b study was performed to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of multiple doses of orally administered LX2761 in patients with type 2 diabetes. Patients were randomly assigned to receive LX2761 or placebo over an 8-day treatment period as either a single dose or twice a day dose at breakfast and dinner. Patients were treated with metformin at the time of screening and for the duration of the study. LX2761 showed reduced postprandial glucose, demonstrating delayed and reduced intestinal glucose absorption while increasing plasma levels of GLP-1 with minimal effect on urinary glucose excretion, consistent with inhibition of intestinal SGLT1. The most common adverse event was diarrhea.
About LX2761
LX2761 is an orally-delivered small molecule compound that is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney. In preclinical studies, LX2761 delayed and reduced intestinal glucose absorption and reduced postprandial glucose while increasing plasma levels of GLP-1 with minimal effect on urinary glucose excretion. Lexicon has granted Sanofi certain rights of first negotiation with respect to the future development and commercialization of LX2761.
About Lexicon Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO® (telotristat ethyl), Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in diabetes and metabolism and neuropathic pain. For additional information please visit www.lexpharma.com.
SOURCE: Lexicon Pharmaceuticals
Post Views: 138
